TCT-121

Relationship Between On-treatment Platelet Reactivity Prior to Coronary Artery Bypass Graft Surgery and In-Hospital Major Bleeding The Surgical Timing Based On Platelet Reactivity for Coronary Artery Bypass Graft Surgery (STOP-CABG) trial

Ron Waksman1, lakshmana Pendyal2, Rebecca Torguson3, Augusto Pichard4, Lowell F. Satler2

1Georgetown University, Washington, United States, 2Washington Hospital Center, Washington, DC, 3Washington Hospital Center, Washington, DC, 4washington hospital center, Washington, United States

Background: Use of aspirin plus thienopyridine increases bleeding risk of coronary artery bypass graft (CABG) surgery. In STOP-CABG trial we prospectively evaluated the association between the pre-operative platelet function testing by different assay methods on the occurrence of post CABG bleeding.

Methods: 81 patients undergoing CABG within 5 days of thienopyridine discontinuation were prospectively enrolled. On-treatment platelet reactivity was measured by Verify Now (VN) P2Y12 assay, Vasodilator Stimulated Phosphoprotein P-threonine (VASP), Night Transmittance Aggregometry (LTA) with 5 and 20 μM of ADP and MAADP by thrombelastography. The primary endpoint was in-hospital major bleeding (IHMB).

Results: IHMB occurred in 38 patients (47%). Median VASP PRI (55.2 vs. 62.5, p=0.003), LTA ADP 5μM (39 vs. 49, p=0.002), LTA ADP 20μM (48.5 vs. 65, p=0.002) and MA ADP mm (40.4 vs. 50.5, p=0.03) was significantly lower in the group with IHMB compared to the group with no major bleeding. In a multivariable logistic regression analysis VASP PRI (OR: 0.96, 95% CI: 0.94-0.99), LTA ADP 5μM (OR: 0.94, 95% CI: 0.91-0.98), LTA ADP 20μM (OR: 0.94, 95% CI: 0.90-0.98) and MA ADP (OR: 0.96, 95% CI: 0.93-1.00) remained as strong correlates of IHMB.

Conclusions: These data prove that in patients affected by VHD and CAD hybrid strategies are safe and may improve outcomes compared to standard surgery, even in higher risk patients undergoing TAVR. Thus, we suggest a more extensive use of CABG combined with valve surgery. Furthermore, we suggest a revision of the current risk scores, as they were designed upon populations treated with conventional surgery and can’t fit these new, evolving scenarios.

TCT-123

Incidence and Impact of Acute Kidney Injury in Patients with Acute Coronary Syndromes Treated with CABG: Insights from ACUITY/HORIZONS-AMI

Josephine Warren1, Roxana Mehran2, Uman Baber3, Ke Xu4, Daniela Giacopelli5, Bernard J Gersh6, Bernard Witzenbichler7, E. Magnus Ohman8, Gregg W. Stone8

1Icahn School of Medicine at Mount Sinai, New York, NY, 2Cardiovascular Research Foundation, New York, NY, 3Mayo Clinic College of Medicine, Rochester, MN, 4Amper Kliniken AG, Dachau, Germany, 5Duke University Medical Center, Durham, NC, 6Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY

Background: Acute kidney injury (AKI) is a well-recognized predictor of morbidity and mortality following PCI. However, the impact of AKI on the outcome of patients with acute coronary syndromes (ACS) undergoing coronary artery bypass graft surgery (CABG) has not been established.

Methods: Of the 17,421 patients who presented with ACS treated with CABG, patients with vs. without AKI had 1-month and 1-year mortality of 6.7% vs. 2.2%, p<0.0001, and 10.4% vs. 4.3%, p<0.0001, respectively. Patients with vs. without AKI had 1-month and 1-year mortality of 6.7% vs. 2.2%, p<0.0001, and 10.4% vs. 4.3%, p<0.0001, respectively. By multivariable analysis, after adjustment for age, gender, race, diabetes, hypertension, and baseline creatinine clearance, AKI was an independent predictor of mortality (overall and cardiac-related), as well as MACE at both 1 month and 1 year following CABG (Figure).

Conclusions: These data prove that in patients affected by VHD and CAD hybrid strategies are safe and may improve outcomes compared to standard surgery, even in higher risk patients undergoing TAVR. Thus, we suggest a more extensive use of CABG combined with valve surgery. Furthermore, we suggest a revision of the current risk scores, as they were designed upon populations treated with conventional surgery and can’t fit these new, evolving scenarios.

Clinical Outcomes in Patients Undergoing Surgical or Percutaneous Revascularization Associated to Valve Surgery

Alexandro Lauddi1, Giovanni Terzic2, Dario Pellegrini3, Luca Grancini4, Alessia Dalla Cia1, Stefano Salis5, Stefano Galli6, Paolo M. Ravagnani7, Daniela Trabattoni8, Piero Montorsi9, Antonio L. Bartorelli10

1University of Milan, Milan, Italy, 2Centro Cardiologico Monzino, Milan, Italy

Background: Patients affected by VHD associated to CAD have a poor short-term prognosis. Even though guidelines recommend traditional valve surgery associated to CABG, it provides limited benefits and a high incidence of short-term complications. Less invasive strategies (i.e. hybrid techniques or PCI + TAVR) have been recently suggested, with interesting results. Aim of our study was to compare the outcomes of these strategies to standard treatment and to assess the risk stratification scores in this setting.

Methods: From 2011 to 2013, 305 patients underwent valve surgery + coronary revascularization. According to the Heart Team suggestions, 225 pts underwent CABG + valve surgery (G1), 30 pts PCI + valve surgery (G2) and 50 pts PCI + TAVR (G3). In each patient we evaluated risk scores (EuroSCORE and STS Score), procedural data and short-term outcomes. Endpoints were defined as occurrence of MACE.

Results: Operative risk was similar in G1 (log EuroSCORE: 7.79 ± 6.1) and G2 (5.67 ± 3.82), but it was significantly higher in G3 (21.2 ± 13.88). Number of treated vessels was 1.57 ± 0.71, 1.3 ± 0.47 and 1.2 ± 0.45, respectively. PCI allowed a significant reduction of operative times (-30’), cross clamp time was 115.68 ± 77.02 min in G1 and 96.13 ± 42.24 in G2 (p=0.008), while ECC time was 150.55 ± 54.87 min vs 120.07 ± 54.94 (p=0.005). Relative Risk for the overall occurrence of a MACE compared to G1 was 0.46 in G2 (p=0.01) and 0.42 in G3 (p<0.001).

Conclusions: These data prove that in patients affected by VHD and CAD hybrid strategies are safe and may improve outcomes compared to standard surgery, even in higher risk patients undergoing TAVR. Thus, we suggest a more extensive use of CABG combined with valve surgery. Furthermore, we suggest a revision of the current risk scores, as they were designed upon populations treated with conventional surgery and can’t fit these new, evolving scenarios.